Division of Hematology/Oncology


faculty photo

Ravi K Amaravadi, MD

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Member, Institute of Translational Medicine and Therapeutics
Member, Abramson Cancer Center
Member, University of Pennsylvania GI Center for Molecular Studies of Digestive and Liver Diseases
Co-Leader Cancer Therapeutics Program , Abramson Cancer Center, University of Pennsylvania
Department: Medicine

Contact information
Hematology-Oncology Division
University of Pennsylvania
16 Penn Tower
3400 Spruce St.
Philadelphia, PA 19104
Office: 215-662-7402
Fax: 215-349-8550
BA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Post-Graduate Training
Internship, Internal Medicine , Brigham and Women's Hospital , 2000-2001.
Resident, Internal Medicine, Brigham and Women's Hospital , 2001-2003.
Fellow, Hematology-Oncology , University of Pennsylvania, 2003-2006.
American Board of Internal Medicine- Internal Medicine , 2003.
American Board of Internal Medicine- Medical Oncology , 2006.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Description of Clinical Expertise

Phase I and Phase II Clinical Trials

Selected Publications

Ma XH, Piao SF, Dey S, Mcafee Q, Karakousis G, Villaneuva J , Hart LS, Levi S, Hu J, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C,Amaravadi RK.: Targeting ER stress induced-autophagy overcomes resistance to BRAF inhibition in melanoma Journal of Clinical Investigation pii: 70454. doi: 10.1172/JCI70454. [Epub ahead of print] (eds.). March 2014.

Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amavaradi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS.: Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigement Cell and Melanoma Research Feb 2014.

Choe, C, Mcarthur GA, Yang M, Caro I, Kempen JH, Amaravadi RK: Ocular Toxicity in BRAF Mutant Melanoma Patients Treated With Vemurafenib accepted, Am J. Ophthalmology 2014.

Dan T. Vogl, Edward A. Stadtmauer, Daniel F. Heitjan, Kay See Tan, Reshma Rangwala, Shengfu Piao, Claire Chang, Emma C. Scott, Thomas M. Paul, Charles W. Nichols, David L. Porter, Janeen Kaplan, Gayle Mallon, James E. Bradner, Lisa E. Davis, Laura Pontiggia, and Ravi K. Amaravadi: Combined autophagy and proteasome inhibition: Phase I trial of hydroxychloroquine with bortezomib in patients with relapsed refractory multiple myeloma. Accepted Autophagy (2012 IF 12) accepted in press 2014.

Akl A, Piao S, Xu G, Zhang G, Gimotty PG, Xu X, Amaravadi RK**, Speicher DW**. **Co-senior authors.: Identification of secreted proteins that reflect autophagy dynamics with tumor cells Preliminarily accepted, Autophagy 2014.

Myrna R. Rosenfeld, Jeffrey G. Supko, Stuart A. Grossman, Steven Brem, Tom Mikkelson, Daniel Wang, Claire Chang, Janice Hu, Quentin McAfee, Andrea Troxel, Shengfu Piao, Daniel Hetjian, Kay See Tan, Laura Pontiggia, Peter J. O’Dwyer, Lisa E. Davis, Ravi K.Amaravadi: A Phase I/II Trial of Hydroxychloroquine in Conjunction with Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme Accepted Autophagy (2012 IF 12) accepted in press 2014.

Reshma Rangwala, Claire Chang, Janice Hu, Kenneth Algazy, Tracey Evans, Leslie Fecher, Lynn Schuchter, Drew Torigian, Andrea Troxel, Kay-See Tan, Dan F. Hetjian, Angela Demichele, David Vaughn, Maryann Redlinger, Abass Alavi, Jonathan Kaiser, Laura Pontiggia, Lisa Davis, Peter J. O’Dwyer, Amaravadi, RK : Combined mTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma Accepted Autophagy (2012 IF 12) submitted for review , accepted in press 2014.

Reshma Rangwala, Robert Leone, Claire Chang, Leslie Fecher, Lynn M. Schuchter, Amy Kramer, Kay-See Tan, Daniel F. Hetjian, Glenda Rodgers, Maryann Gallagher, Shengfu Piao, Andrea B. Troxel, Tracey Evans, Angela DeMichele, Katherine L. Nathanson, Peter J. O’Dwyer , Jonathan Kaiser Laura Pontiggia, Lisa E. Davis, Ravi K. Amaravadi: Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma Accepted Autophagy (2012 IF 12) accepted in press 2014.

Devalingam Mahalingam, Monica Mita, John Sarantopoulos, Ravi Amaravadi, Lisa Davis, Alain Mita1, Tyler Curiel, Steffan T. Nawrocki, Francis J. Giles, Jennifer S. Carew : Combined Inhibition of Autophagy and HDAC inhibition: A Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Analysis of Hydroxychloroquine in Combination with the HDAC Inhibitor Vorinostat in Patients with Advanced Solid Tumors Accepted Autophagy (2012 IF 12) accepted in press 2014.

Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH: Phase I and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in dogs with spontaneously occurring lymphoma. Autophagy accepted in press 2014.

back to top
Last updated: 04/16/2014
The Trustees of the University of Pennsylvania

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter